← Leaderboards
Xiongbin Lu
Indiana University Indianapolis
$8,023,409
Attributed
$12,545,060
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–23$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,545,060 · 11
By mechanism
R01$11,450,142 · 6
R21$773,907 · 2
P20$177,540 · 2
R03$143,471 · 1
Top collaborators
- Xiaoming He10 shared
- Deepak Nagrath5 shared
- Xinna Zhang5 shared
- Bryan Paul Schneider3 shared
- Jin Wang2 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Xinna Zhang$3,467,211
- Bryan Paul Schneider$1,500,312
- Mateusz Opyrchal$1,160,437
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMediatingTumorTp53 GeneMalignant Breast NeoplasmCancer CellGenomicsCellsBaseMouse ModelIn VivoColorectal CancerGenesIn VitroMutationSignal TransductionResistanceOverexpressionPublishingMalignant Neoplasm Of OvaryTumorigenicCancer TherapyPolr2a GeneTumor Suppressor Proteins
Grant awards (40)
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2023 · CA · contact PI
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$491,792
R01 · FY2023 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer$441,858
R01 · FY2023 · CA
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2022 · CA · contact PI
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$501,827
R01 · FY2022 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer$441,579
R01 · FY2022 · CA
Identification of USP13 as a therapeutic target for ovarian cancer$347,513
R01 · FY2022 · CA · contact PI
Targeting HER2-low breast cancer with 17p loss$535,448
R01 · FY2021 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer$455,670
R01 · FY2021 · CA
Identification of USP13 as a therapeutic target for ovarian cancer$357,498
R01 · FY2021 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer$472,539
R01 · FY2020 · CA
Nanotechnology enabled targeting of p53 deficiency in human cancer$463,867
R01 · FY2020 · CA
Targeting Human Cancers with Hemizygous Deletion of TP53$360,281
R01 · FY2020 · CA · contact PI
Identification of USP13 as a therapeutic target for ovarian cancer$360,271
R01 · FY2020 · CA · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$42,815
R01 · FY2020 · CA
Identification of USP13 as a therapeutic target for ovarian cancer$352,044
R01 · FY2019 · CA · contact PI
Targeting Human Cancers with Hemizygous Deletion of TP53$349,472
R01 · FY2019 · CA · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$343,342
R01 · FY2019 · CA
Identification of USP13 as a therapeutic target for ovarian cancer$379,129
R01 · FY2018 · CA · contact PI
Targeting Human Cancers with Hemizygous Deletion of TP53$360,281
R01 · FY2018 · CA · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$353,962
R01 · FY2018 · CA
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer$207,797
R21 · FY2018 · CA
Targeting Human Cancers with Hemizygous Deletion of TP53$360,281
R01 · FY2017 · CA · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$359,138
R01 · FY2017 · CA
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer$185,933
R21 · FY2017 · CA
Nanotechnology enabled targeting of p53 deficiency in human cancer$371,490
R01 · FY2016 · CA
Targeting Human Cancers with Hemizygous Deletion of TP53$366,000
R01 · FY2016 · CA · contact PI
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling$165,285
R21 · FY2016 · CA · contact PI
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling$6,092
R21 · FY2016 · CA · contact PI
Ubiquitin specific peptidases as redox sensor in oncogene-induced p53 signaling$208,800
R21 · FY2015 · CA · contact PI
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas$298,935
R01 · FY2013 · CA · contact PI
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas$318,015
R01 · FY2012 · CA · contact PI
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas$318,015
R01 · FY2011 · CA · contact PI
ROLE OF PROTEIN PHOSPHATASES IN THE DNA DAMAGE RESPONSE$35,375
P20 · FY2011 · RR · contact PI
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas$298,800
R01 · FY2010 · CA · contact PI
ROLE OF PROTEIN PHOSPHATASES IN THE DNA DAMAGE RESPONSE$142,165
P20 · FY2010 · RR · contact PI
Identification of Novel Protein Phosphatases in the ATM Signaling Pathway$47,820
R03 · FY2010 · CA · contact PI
Identification of Novel Protein Phosphatases in the ATM Signaling Pathway$25,883
R03 · FY2010 · CA · contact PI
Regulation of the ATM/ATR-p53 DNA Damage Signaling Pathway by the Wip1 Phosphatas$298,800
R01 · FY2009 · CA · contact PI
Identification of Novel Protein Phosphatases in the ATM Signaling Pathway$69,768
R03 · FY2009 · CA · contact PI